Journal
BRITISH JOURNAL OF CANCER
Volume 125, Issue 3, Pages 313-323Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-021-01365-2
Keywords
-
Categories
Funding
- Lungenliga St. Gallen-Appenzell
Ask authors/readers for more resources
Tumour neoantigens from cancer-specific mutations distinguish cancer from healthy cells, but microbial species can produce epitopes resembling tumour neoantigens, leading to tumour molecular mimicry. Microbiome-mediated tumour neoantigen mimicry may impact the efficacy of immune therapy.
Tumour neoantigens arising from cancer-specific mutations generate a molecular fingerprint that has a definite specificity for cancer. Although this fingerprint perfectly discriminates cancer from healthy somatic and germline cells, and is therefore therapeutically exploitable using immune checkpoint blockade, gut and extra-gut microbial species can independently produce epitopes that resemble tumour neoantigens as part of their natural gene expression programmes. Such tumour molecular mimicry is likely not only to influence the quality and strength of the body's anti-cancer immune response, but could also explain why certain patients show favourable long-term responses to immune checkpoint blockade while others do not benefit at all from this treatment. This article outlines the requirement for tumour neoantigens in successful cancer immunotherapy and draws attention to the emerging role of microbiome-mediated tumour neoantigen mimicry in determining checkpoint immunotherapy outcome, with far-reaching implications for the future of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available